31 results about "Immune effector" patented technology

A method for treating a tumor, characterized by administering to an individual having a tumor immune effector cells expressing a receptor recognizing a tumor antigen and gemcitabine. A kit for treating a tumor, characterized by comprising: 1) immune effector cells expressing a receptor recognizing a tumor antigen; 2) gemcitabine; 3) a container for containing the above 1) and 2); and 4) a written notice for treating a tumor using the kit.

The present application discloses immune effector cells expressing extracellular PD-L1 binding domain CAR and linking secretory interferon fusion protein and application methods thereof. The protein construct involved in the immune effector cells includes: (a) a chimeric antigen receptor (CAR) containing a PD-L1 binding domain; and (b) a secretory fusion protein containing IFN. The protein construct stimulates tumor cells to increase the expression amount or frequency of PD-L1, thereby further enhancing the killing ability of PD1-CAR-T cells on target cells and more effectively inhibiting or killing tumor cells.

To provide a method and composition for generating induced non-pluripotent cells differentiated from single-cell induced iPSC (induced pluripotent stem cell) clone lines. [Solution] A method and composition are provided for obtaining functionally enhanced induced effector cells obtained from targeted differentiation of genome-manipulated iPSCs. The iPSC-induced cells provided herein have stable functional genome editing that results in improved or enhanced therapeutic effects. Therapeutic compositions and their use are also provided, comprising functionally enhanced induced effector cells alone or in combination therapy with antibodies or checkpoint inhibitors.

This invention discloses an engineered attenuated Salmonella VNP-SNase, its preparation method, and its applications, including methods and compositions for treating various solid tumors or metastatic tumors. Specifically, engineered attenuated Salmonella capable of expressing and secreting SNase is recruited to the tumor microenvironment through tumor targeting, specifically degrading intratumoral neutrophil extracellular traps (NETs), weakening the killing effect of NETs on Salmonella, increasing its intratumoral colonization, and simultaneously improving the tumor-promoting and immunosuppressive effects caused by NETs, ​​while effectively preventing bacteria from off-target into normal organs. By releasing SNase to activate / regulate the immune system and directly / indirectly inhibit tumors, it can act as an effective immune effector.

The disclosure relates to chimeric antigen receptors and immune effector cells bearing chimeric antigen receptors (CARs). Disclosed herein are improved methods of making immune effector cells that use stimulation with or exposure to one or more antibodies specific for the TCR-CD3 complex, such as, for example, an anti-CD3 antibody. Stimulation / exposure is used either in place of or in combination with a magnetic depletion step. The immune effector cells produced by such methods are functionally comparable to and / or have fewer TCR+ cells and show efficacy and stability relative to immune effector cells sorted via magnetic depletion.

The disclosure relates to a chimeric antigen receptors (CARs) specific for one or more glioma-associated antigens and an immune effector cell or a population of immune effector cells expressing one or more CARs specific for one or more glioma-associated antigens. The disclosure also relates to a method of making the immune cell or population, a method of treating cancer using the immune cell or population.

The present invention relates to biotechnology and is based on the identification of sets of IL-2 mutations in the vicinity of the interface with the receptor beta chain, through the selection of variants from filamentous phage libraries by affinity to the extracellular domain of the beta chain. Recombinant proteins derived from these variants show a very favourable developability profile, in terms of high expression levels, low tendency to aggregate, and high thermal stability. In addition, compared to the original unmutated IL-2 and to other described superagonist muteins, they have a higher capacity to stimulate immune effector populations carrying the dimeric IL-2 receptor and a higher anti-tumour activity in vivo.

As described below, the present disclosure features modified immune effector cells (e.g., T or NK cells) having increased resistance to inhibition by immunosuppressant agents relative to unmodified immune effector cells, compositions containing the same, and methods for use thereof.

This document discloses antibodies targeting CD40 and their uses. It also discloses novel antigen-binding proteins capable of specifically binding to CD40 and their antigen-binding fragments. Furthermore, this document discloses fusion proteins comprising a first domain activating antigen-presenting cells (APCs) (e.g., dendritic cells) and a second domain activating immune effector cells (e.g., T cells), wherein the first domain comprises the antigen-binding protein or its antigen-binding fragment that specifically binds to CD40 disclosed herein.

The present invention features genetically modified immune cells comprising novel adenosine base editors (e.g., ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.

The present disclosure provides compositions and methods comprising recombinant particles suitable for the in vivo delivery of one or more chimeric antigen receptor specificities to immune effector cells.

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

The present application provides single domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains, each comprising a single domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Also provided are pharmaceutical compositions, kits, and methods of treating cancer.

Methods and compositions are provided for obtaining functionally enhanced induced effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable, functional genome editing that results in improved or enhanced therapeutic effects. Therapeutic compositions and uses thereof are also provided, comprising the functionally enhanced induced effector cells alone or in combination with antibodies or checkpoint inhibitors in combination therapy.

Provided is an anti-Claudin18.2 nanobody or a binding fragment thereof. The antibody has good specificity, and immune effector cells targeting Claudin18.2 which are prepared from the antibody show a good therapeutic effect in treating or ameliorating diseases having positive expression of Claudin18.2.

Aspects of the present disclosure include synapse-stabilizing receptors comprising a LAT domain that can be used in combination with a CAR, TCR, or BiTE. Another aspect of the present disclosure is immune cells comprising synapse-stabilizing receptors comprising a LAT domain that can be used in combination with a CAR, TCR, or BiTE, and methods of their use in treating a disease (e.g., cancer).

Feline, canine, and equine antibody variants and uses thereof, as well as compositions and methods for improving therapeutic monoclonal antibodies by modulating immune effector functions and antibody variants using those methods and compositions.

The invention relates to a delta-like ligand 3 targeting CAR-T cell and application, and particularly provides nucleic acid of a chimeric antigen receptor coding the delta-like ligand 3, the corresponding chimeric antigen receptor, a carrier, an immune effector cell, a preparation method, a product of the chimeric antigen receptor, a pharmaceutical composition, pharmaceutical application and a tumor or cancer treatment method.

Provided are anti-IL13RA2 single domain antibodies (e.g., VHH domain antibodies), and chimeric antigen receptors (CARs) that binds IL 13RA2 comprising same in an extracellular antigen binding domain, a transmembrane domain, and an intracellular CN signaling domain. Immune effector cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.

Disclosed herein are therapeutic uses for treating cancer in a subject in need thereof, comprising administering to the subject a population of chimeric antigen receptor (CAR)-bearing immune effector cells and an IL-7 protein (e.g., modified IL-7 protein).

The application provides an immune cell activity evaluation method, and belongs to the technical field of immunology. The method carries out pre-stimulation on immune cells by using a cytokine mixed solution containing IL-6 and TNF-α, and then carries out co-culture of the pretreated peripheral blood and a logarithmic growth phase target cell suspension, carries out staining and dark incubation, and then carries out detection by using a flow cytometer to calculate the target cell apoptosis ratio. Meanwhile, the mononuclear cells are separated and induced into immune effector cells and are expanded and cultured, the fluorescently labeled target cells are co-incubated with the immune effector cells, and then the killing rate of the immune effector cells on the target cells is calculated. On this basis, the target cell suspension and the immune cell suspension are mixed and incubated according to the effector-target ratio, PI staining solution is added for incubation, and finally the flow cytometer is used to detect the target cell apoptosis rate. Compared with the prior art, the sensitivity of the application is significantly improved, the results have strong comparability, the detection and evaluation process is simple and efficient, and there is no safety risk.

A chimeric antigen receptor (CAR) capable of targeting antigens expressed by disease-associated cells (e.g., tumor cells), such as a CD19-specific CAR. A polynucleotide encoding a CAR and optionally: i) a miRNA silencing module capable of inhibiting the expression of immune checkpoint proteins (e.g., PD-1); ii) cytokines (e.g., membrane-bound IL-15); and / or cell tags (e.g., HER-1 kill switches). A vector comprising the polynucleotide. Modified immune effector cells comprising a CAR, a polynucleotide, or a vector. Compositions and kits comprising a CAR, a polynucleotide, a vector, and / or modified immune effector cells. Use of CARs, polynucleotides, vectors, and / or modified immune effector cells in the preparation of medicaments for treating diseases or conditions. A method of treating a subject suffering from a disease or condition, comprising administering a CAR, a polynucleotide, a vector, and / or modified immune effector cells to the subject in need.

The present invention features genetically modified immune cells comprising novel adenosine base editors (e.g., ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.

The disclosure relates to chimeric antigen receptors and immune effector cells bearing chimeric antigen receptors (CARs). Disclosed herein are improved methods of making immune effector cells that use stimulation with or exposure to one or more antibodies specific for the TCR-CD3 complex, such as, for example, an anti-CD3 antibody. Stimulation / exposure is used either in place of or in combination with a magnetic depletion step. The immune effector cells produced by such methods are functionally comparable to and / or have fewer TCR+ cells and show efficacy and stability relative to immune effector cells sorted via magnetic depletion.

The application discloses a specific T cell epitope peptide screened by a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicine, and its technical points are: the application provides a plurality of CD4+ T and CD8+ T cell epitope polypeptides of the novel coronavirus, and the genes, recombinant proteins or complexes containing the epitope polypeptides, sensitized antigen presenting cells and specific immune effector cells for the epitope polypeptides are used in the development of a novel coronavirus vaccine and the treatment of diseases.The polypeptide provided by the application is screened from the peripheral blood sample of a recovered person who breaks through infection of Omicron BA.5 after inactivated vaccine booster vaccination, and can safely and effectively induce CD4+ T and CD8+ T cell immune responses to the novel coronavirus protein, and has important guiding significance for the development of a novel coronavirus vaccine.

This invention relates to the screening of MAGE-A4-specific T-cell receptors and their anti-tumor applications. Specifically, this invention provides a T-cell receptor TCR or its antigen-binding fragment, wherein the TCR or its antigen-binding fragment is capable of binding to MAGE-A4. 146‑154 The TCR binds to the epitope and the HLA-A11 complex, and the TCR contains an α-chain variable region and a β-chain variable region. The TCR or its antigen-binding fragment contains the following α-chain complementarity-determining regions (CDRs): α-chain complementarity-determining region CDR1 as shown in SEQ ID NO:10, α-chain complementarity-determining region CDR2 as shown in SEQ ID NO:11, α-chain complementarity-determining region CDR3 as shown in SEQ ID NO:12, β-chain complementarity-determining region CDR1 as shown in SEQ ID NO:14, β-chain complementarity-determining region CDR2 as shown in SEQ ID NO:15, and β-chain complementarity-determining region CDR3 as shown in SEQ ID NO:16. The specific T-cell receptor and its antigen-binding fragment can act as immune effector activators to stimulate the body's immune response, thereby producing anti-tumor and other disease-fighting effects.